Trastuzumab Rezetecan in Advanced Solid Tumors Refractory to Standard Therapies

NCT ID: NCT07309770

Last Updated: 2025-12-30

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE2
• Total Enrollment: 90 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-12-18
• Study Completion Date: 2028-03-11

Brief Summary

This study is a single-center, multi-cohort, phase II clinical trial. Eligible patients with HER2-positive advanced solid tumors were enrolled after providing informed consent. A total of 90 patients were allocated into three cohorts (30 patients each): those with Extramammary Paget's Disease (EMPD), rare solid tumors, or urothelial carcinoma, who had experienced failure of standard treatment or for whom no standard treatment was available. The participant recruitment period was 12 months, and the follow-up duration was 12 months. All patients received Trastuzumab Rezetecan (SHR-A1811) at a dose of 4.8 mg/kg administered every three weeks (q3w). They were followed until disease progression, withdrawal from the study, loss to follow-up, or death, whichever occurred first. Tumor response was assessed radiologically every 6 weeks during treatment. Safety follow-up was conducted 30 days after the last dose, followed by survival follow-up every 3 months thereafter.

Conditions

Urachal Cancer; Advanced Solid Tumor Cancer; Antibody-drug Conjugates

Keywords

Antibody-Drug Conjugates; Rare tumor; Extra-mammary Paget disease; Urachal cancer; Trastuzumab Rezetecan

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Experimental group 1

Cohort1:Patients with histologically confirmed extramammary Paget's disease (EMPD) demonstrating HER2 expression (IHC ≥ 1+) and having unresectable locally advanced or metastatic disease.

Cohort2: Patients with histologically confirmed locally advanced or metastatic rare solid tumors (such as sarcoma, urachal carcinoma, etc.) demonstrating HER2 expression (IHC ≥ 1+) , who have experienced disease progression on or after standard therapy, or for whom no standard therapy is available, and with at least one measurable lesion.

Cohort3:Patients with histologically confirmed locally advanced or metastatic urothelial carcinoma demonstrating HER2 expression (IHC ≥ 1+) , who have experienced disease progression following first-line treatment with a PD-1/PD-L1 inhibitor in combination with Enfortumab Vedotin or Disitamab vedotin

Group Type: EXPERIMENTAL

SHR-A1811

Intervention Type: DRUG

Trastuzumab Rezetecan (SHR-A1811) is administered at a dose of 4.8 mg/kg every 21 days (q3w), constituting one treatment cycle.

Trastuzumab Rezetecan

Intervention Type: DRUG

Patients who have failed standard therapy are treated with Trastuzumab Rezetecan

Interventions

SHR-A1811

Trastuzumab Rezetecan (SHR-A1811) is administered at a dose of 4.8 mg/kg every 21 days (q3w), constituting one treatment cycle.

Intervention Type: DRUG

Trastuzumab Rezetecan

Patients who have failed standard therapy are treated with Trastuzumab Rezetecan

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

Voluntarily sign a written informed consent form.

Age ≥ 18 years.

Diagnosed with the corresponding advanced tumor confirmed by histology and/or cytology, combined with imaging or ultrasound assessment, and pathologically confirmed as HER2-positive (i.e., HER2 ≥ 1+ by immunohistochemistry [IHC]).

Cohort 1 only: Histologically confirmed extramammary Paget's disease (EMPD) with unresectable locally advanced or metastatic disease.

Cohort 2 only: Histologically confirmed locally advanced or metastatic rare solid tumor (e.g., sarcoma, urachal cancer) refractory to standard treatment or for whom no standard treatment is available.

Cohort 3 only: Histologically confirmed locally advanced or metastatic urothelial carcinoma with disease progression following first-line treatment with a PD-1/PD-L1 inhibitor combined with enfortumab vedotin or disitamab vedotin.

ECOG Performance Status: 0 to 2.

At least one measurable lesion (according to RECIST v1.1 criteria: non-nodal lesions with longest diameter ≥10 mm on CT scan, nodal lesions with short axis ≥15 mm on CT scan).

Hematological function:

Absolute Neutrophil Count (ANC) ≥ 1.5 × 10⁹/L

Platelet count (PLT) ≥ 70 × 10⁹/L

Hemoglobin (HGB) ≥ 80 g/L

Hepatic function:

Serum total bilirubin (TBIL) ≤ 1.5 × Upper Limit of Normal (ULN)

Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST) ≤ 3 × ULN (≤ 5 × ULN if liver metastases are present)

Serum albumin ≥ 28 g/L

Renal function:

Serum creatinine (Cr) ≤ 1.5 × ULN or Creatinine clearance ≥ 50 mL/min (calculated using the standard Cockcroft-Gault formula)

Coagulation function:

International Normalized Ratio (INR) ≤ 1.5 and/or Prothrombin Time (PT) ≤ 1.5 × ULN

Activated Partial Thromboplastin Time (aPTT) ≤ 1.5 × ULN

Estimated life expectancy ≥ 3 months.

Use of medically approved contraception during the treatment period and for at least 120 days after the end of the study; sperm donation or cryopreservation for fertilization purposes is not allowed during this period.

Ability to comply with the study visit schedule and other protocol requirements.

History of immunodeficiency, including HIV positivity or other acquired or congenital immunodeficiency diseases.

Known history of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation.

Known presence of brain metastases, leptomeningeal metastasis, spinal cord compression, or spinal metastasis.

Within 6 months prior to the first dose: history of esophageal/gastric varices, severe ulcer, unhealed wound, gastrointestinal perforation, abdominal fistula, intestinal obstruction, intra-abdominal abscess, acute gastrointestinal bleeding; extensive intestinal resection (partial colectomy or extensive small bowel resection with chronic diarrhea), Crohn's disease, ulcerative colitis, or chronic diarrhea.

Presence of non-healing or poorly healed wounds, active ulcers.

Toxicity from previous antineoplastic therapy that has not resolved to ≤ Grade 1 per NCI CTCAE v5.0 (except for alopecia).

Major surgical treatment, open biopsy, or significant traumatic injury within 28 days prior to the start of study treatment; or presence of long-term unhealed wounds or fractures.

History of severe hypersensitivity reaction to monoclonal antibodies; known allergy to the active components or excipients of the study drug(s).

Participation in another clinical trial within 4 weeks prior to the start of the study.

Administration of a live vaccine within 30 days prior to the first dose, or planned administration during the study.

History of severe allergy.

Bleeding tendency, coagulopathy, or undergoing thrombolytic therapy.

History of drug abuse or inability to discontinue use, or history of psychiatric disorders.

History of clear neurological or psychiatric disorders, such as dementia, epilepsy, or susceptibility to seizures.

Any condition that, in the investigator's judgment, seriously endangers subject safety, affects subject completion of the study (e.g., severe diabetes, thyroid disease, psychosis), may compromise subject safety or the ability to provide informed consent (including abnormal laboratory findings), or involves psychological, familial, sociological, or geographical conditions that may preclude compliance with the study protocol and follow-up plan.

Any other reason deemed by the investigator to make the subject unsuitable for participation in this clinical trial.

Exclusion Criteria

Subjects who meet any of the following criteria will be excluded from participation in this study:

Presence of any severe and/or uncontrolled disease, including:

Poorly controlled hypertension (systolic blood pressure ≥ 150 mmHg or diastolic blood pressure ≥ 100 mmHg); poorly controlled diabetes (fasting blood glucose [FBG] > 10 mmol/L).

≥ Grade 2 myocardial ischemia, myocardial infarction, arrhythmia (QTcF ≥ 470 ms), or ≥ Grade 2 congestive heart failure (New York Heart Association [NYHA] classification).

Active or uncontrolled severe infection (≥ CTCAE Grade 2 infection) requiring systemic antibacterial, antifungal, or antiviral treatment, including tuberculosis infection.

History of active tuberculosis.

Uncontrolled ascites, pericardial effusion, or pleural effusion requiring repeated drainage.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Sheng Zhang

OTHER

Sponsor Role: lead

Responsible Party

Sheng Zhang

Prof.

Responsibility Role: SPONSOR_INVESTIGATOR

Locations

Fudan University Shanghai Cancer Center

Shanghai, Shanghai Municipality, China

Site Status: RECRUITING

Countries

China

Central Contacts

Sheng Zhang

Role: CONTACT

Phone: +86 021-64175590

Email: wozhangsheng@hotmail.com

Facility Contacts

Sheng ZHANG

Role: primary

Other Identifiers

A1811-US-03

Identifier Type: -

Identifier Source: org_study_id